Conflict of Interest

This website is hosted at Women’s College Hospital and was developed using funds from grants from Eczema Society of Canada and the Innovation Fund of the Alternate Funding Plan for the Academic Health Sciences Centres of Ontario. The network meta-analysis itself is not funded. There is no industry funding for this prioject.

Individual investigator declarations are as follows:

Dr. Drucker has no financial ties with any pharmaceutical company since 2017. In the last 3 years, Dr. Drucker has been a consultant for  Canadian Agency for Drugs and Technology in Health. He has received honoraria from CME Outfitters, National Eczema Association, American Academy of Dermatology and British Journal of Dermatology.

Dr. Flohr is Chief Investigator of the UK NIHR-funded TREAT and SOFTER trials as well as the UK-Irish Atopic eczema Systemic Therapy Register (A-STAR) and an investigator in the Horizon 2020 funded BIOMAP Consortium. His department has also received funding from Sanofi-Genzyme for skin microbiome work.

Denise Küster and Doreen Siegels received institutional funding for IITs from Novartis, Sanofi, Pfizer, ALK.

Prof. dr. Ph.I. Spuls is chief investigator of the Governmental funded TREAT NL registry ( and principal investigator of the MAcAD RCTs (Schram et al, JACI 2011, Roekevisch et al, JACI 2018, Gerbens et al. BJD 2018). She has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), received 2 independent research grants in the past > 5 years ago, and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis for which we get financial compensation paid to the department/hospital.

Dr. Schmitt received institutional funding for IITs from Novartis, Sanofi, Pfizer, ALK. He received fees for consulting from Novartis and Pfizer. Dr. Schmitt was principle investigator of a trial included in this review. He is co-PI of the German national AD registry TREATgermany, which is funded by Sanofi.